Autolus Sells AUTO1/299 to BioNTech for $100M Upfront

TL;DR

Autolus sells AUTO1/299 to BioNTech for $100M upfront, focusing on core assets.

AI Summary

Autolus Therapeutics plc announced on May 13, 2024, that it has entered into a definitive agreement to sell its AUTO1/299 program to BioNTech SE for an upfront payment of $100 million, with potential for an additional $100 million in milestone payments. This transaction is expected to close in the second quarter of 2024.

Why It Matters

This divestiture allows Autolus to focus on its core AUTO1 and AUTO3 programs, potentially strengthening its financial position and strategic direction.

Risk Assessment

Risk Level: medium — The sale of a program and reliance on future milestones introduce financial and strategic risks.

Key Numbers

• $100.0M — Upfront Payment (Received from BioNTech for AUTO1/299 program)
• $100.0M — Potential Milestone Payments (Additional payments from BioNTech)

Key Players & Entities

• Autolus Therapeutics plc (company) — Seller
• BioNTech SE (company) — Buyer
• AUTO1/299 (program) — Divested asset
• $100 million (dollar_amount) — Upfront payment
• $100 million (dollar_amount) — Potential milestone payments
• May 13, 2024 (date) — Announcement date
• second quarter of 2024 (date) — Expected closing period

FAQ

From the Filing

0001193125-24-136696.txt : 20240513 0001193125-24-136696.hdr.sgml : 20240513 20240513072304 ACCESSION NUMBER: 0001193125-24-136696 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240513 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240513 DATE AS OF CHANGE: 20240513 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Autolus Therapeutics plc CENTRAL INDEX KEY: 0001730463 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38547 FILM NUMBER: 24936870 BUSINESS ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP BUSINESS PHONE: 44 20 3829 6230 MAIL ADDRESS: STREET 1: THE MEDIAWORKS STREET 2: 191 WOOD LANE CITY: LONDON STATE: X0 ZIP: W12 7FP FORMER COMPANY: FORMER CONFORMED NAME: Autolus Therapeutics Ltd DATE OF NAME CHANGE: 20180205 8-K 1 d810087d8k.htm 8-K 8-K 00-0000000 0001730463 false 0001730463 2024-05-13 2024-05-13 0001730463 sic:Z8880 2024-05-13 2024-05-13 0001730463 us-gaap:CommonClassAMember 2024-05-13 2024-05-13     UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024     Autolus Therapeutics plc (Exact name of registrant as specified in its Charter)       England and Wales   001-38547   Not applicable (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (I.R.S. Employer Identification No.) The MediaWorks 191 Wood Lane London W12 7FP United Kingdom (Address of principal executive offices) (Zip Code) (44) 20 3829 6230 (Registrant’s telephone number, including area code) Not Applicable (Former name or former address, if changed since last report)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered American Depositary Shares, each representing one ordinary share, nominal value $0.000042 per share   AUTL   The Nasdaq Global Select Market Ordinary shares, nominal value $0.000042 per share*   *   The Nasdaq Stock Market LLC *   * Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Global Select Market. The American Depositary Shares represent the right to receive ordinary shares and are being registered under the Securities Act of 1933, as amended, pursuant to a separate Registration Statement on Form F-6. Accordingly, the American Depositary Shares are exempt from the operation of Section 12(a) of the Securities Exchange Act of 1934, as amended, pursuant to Rule 12a-8 thereunder. Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company